PARIS, May 23, 2022 /PRNewswire/ Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform
Data highlights strong immune responses and early signs of clinical benefit, establishing proof-of-concept OncoMimics immunotherapy pipeline generated using Enterome's unique microbiome
PARIS, April 5, 2022 /PRNewswire/ Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial effector-based drug discovery
- First clinical proof of concept data with lead OncoMimics therapeutic cancer vaccine candidate EO2401 expected in H1 2022 - New Corporate Identity and Website Launched Today PARIS
/PRNewswire/ Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its unique ability to decode the.